Hjem › Akut bifænotypisk leukæmi › Washington
Akut bifænotypisk leukæmi kliniske forsøg i Washington
15 studier for Akut bifænotypisk leukæmi søger deltagere på steder i Washington.
Byer i Washington
Officiel studietekst (engelsk)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1
Alder 12 til 78 · Alle køn · Opdateret 29. sep. 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT04375631Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07094750Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- og 1 flere
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 2
6 Months – 65 Years · Alle køn · Opdateret 22. jul. 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. jul. 2026 · NCT07046078211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 22. jun. 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 22. jun. 2026 · NCT03670966Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 2Frivillige med god helbredstilstand velkomne
6 Months · Alle køn · Opdateret 29. maj 2026 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1
Op til 80 år · Alle køn · Opdateret 18. maj 2026 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1/2Frivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 15. maj 2026 · NCT06928662Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT04797767Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Seattle Children's Hospital, Seattle
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.